Rebaudioside A

DB15136InvestigationalSmall molecule

Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

Mechanism: Pharmacologically active on Taste receptor type 1 member 2 and Taste receptor type 1 member 3
Curator reviewed
Formula / weight: C₄₄H₇₀O₂₃ · 967.021 g/mol (avg)

Resolves to

Compound

UNIIB3FUD0528FCAS58543-16-1ChEBI145012

Clinical / RWD

RxNorm1667222

Structure

InChIKeyHELXLJCILKEWJH-NCGAPWICSA-NSMILES

C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

Targets

Q8TE23TAS1R2Q7RTX0TAS1R3

What you can answer from here — as of September 12, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rebaudioside A, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account